Medical School
Hacettepe University Medical Faculty
Post-Graduate Training
Hacettepe University Medical Faculty
Professional Experience
Hacettepe University Medical Faculty Internal Medicine 2006-2011
Hacettepe Medical Faculty Oncology 2011-2015
SBÜ Konya Education & Research Hospital 2015-2016
Medicana International Ankara Hospital 2016-2018
İstinye University Medical Faculty - Medical Park Trabzon Hospital (2018-2020)
Medical Interests
Breast cancerColon cancerLung cancerLymphoma
Special Procedures
Scientific Publications
1)Sarici F, Sunar V, Aksoy S. The Frequency and Determinants of Metabolic Syndrome in Operated Patients with Stage I-III Breast Cancer. International Journal of Hematology and Oncology 2020; 30(1):1-10.
2)Sarici F, Babacan T, Büyükhatipoglu H et al. Correlation of educational status and clinicopathological characteristics of breast cancer: a single center experience. J BUON.2016;21(4):826-31.
3) Sarici F, Kertmen N, Aslan A, Taşdemir V, Babacan T, Kilickap S, Ozdemir E, Barista İ, Türker A, Kars A. Anthracyclin – Based Chemotherapy in Patients with Non-Hodgkin Lymphoma Aged Over 75. International Journal of Hematology and Oncology 2016; 26(2):089-095.
4)Ateş O, Babacan T, Kertmen N, Sarici F, Cenoli A, Akin S, Karakaş Y, Kilickap S, Ozisik Y, Sever AR, Aksoy S, Altundağ K.Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer. J BUON. 2016;21(2):375-81.
5)Ateş O, Soylu C, Babacan T, Sarici F, Kertmen N, Allen D, Sever AR, Altundağ K.Assessment of psychosocial factors and distress in women having adjuvant endocrine therapy for breast cancer: the relationship among emotional distress and patient and treatment-related factors. Springerplus. 2016;19(5):486.
6)Sarici F, Babacan T, Altudağ K, Balakan O, GulluI. Successful treatment of benign metastasizing leiomyoma with oral alternated chemotherapeutic agents. J BUON.2013;18(3):799.
7)Solak M, Turkoz FP, Keskin O, Aksoy S, Babacan T, Sarici F, Kertmen N, Sever AR, Altundağ K. The lymph node ratio as an independent prognostic factor for non-metastatic node-positive breast cancer recurrence and mortality. J BUON.2015;20(3):737-45.
8)Babacan T, Balakan O, Kuzan TY, Sarici F, Koca E, Kertmen N, Petekkaya I, Altundağ K. The effect of renin-angiotensin-system inhibition on survival and recurrence of N3+ breast cancer patients. J BUON.2015;20(1):50-6.
9)Babacan T, Efe O, Hasirci AS, Demirci F, Büyükhatipoğlu H, Balakan O, Sarici F, Kertmen N, Esin E, Akin S, Ateş O, Aksoy S, Sever AR, Altundağ K. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer. Tumori.2015;101(4):418-23.
10)Sarici F, Babacan T, Petekkaya I, Gezgen G, Roach EC, Altundağ K. Colon involvement in a chronic lymphocytic leukemia patient. J BUON. 2013;18(1):291-2.
11)Kertmen N, Babacan T, Keskin O, Solak M, Sarici F, Akın S, Arik Z, Aslan A, Ateş O, Aksoy S, Ozisik Y, Altundağ K. Molecular subtypes in patients with inflammatory breast cancer; a single center experience. J BUON. 2015;20(1):35-9.
Memberships:Associatio of Internal Medicine SpecialistsMedical Oncology AssociationAnkara Chamber of Medicine (Turkish Medical Association)
